Abstract
Blood eosinophils predict the response to therapy, risk of exacerbation, and readmission in COPD. This study investigates whether blood eosinophils predict pulmonary rehabilitation (PR) outcomes in COPD.
We categorized patients into eosinophilic (blood eosinophils ≥300 cells/ml) or noneosinophilic (<300 cells/ml). In a retrospective design, we compared changes within and between the two groups on BODE index, 6-minute walk test (6MWT), FEV1, and mMRC dyspnea scale.
Of 206 patients enrolled, 176 were included for analysis; 90 were eosinophilic. BODE index improved in both groups: (MD -1.25; 95% CI (-0.45, -4.25),
≤ 0.001) in the eosinophilic and (MD -1.33; 95% CI (-1.72, -0.94),
≤ 0.001) in the noneosinophilic, but a higher BODE index remained in the eosinophilic (4.98); adjusted mean change (
): 0.7 (95% CI (0.15, 1.26),
=0.01). 6MWT improved by 29.3 m in the eosinophilic (95% CI (14.2, 44.4),
≤ 0.001) vs. 115.1 m in the noneosinophilic (95% CI (-30.4, 260.6),
=0.12). FEV1 did not change in the eosinophilic (MD -0.6; 95% CI (-2.64, 1.48),
=0.58), but improved by 2.5% in the noneosinophilic (MD 2.5; 95% CI (0.77, 4.17),
=0.005). There were no significant between-group differences in 6MWT and FEV1; adjusted mean changes (
) were -9.69 m (95% CI (-39.51, 20.14),
=0.52) and -2.31% (95% CI (-5.69, 1.08),
=0.18), respectively. There were no significant within- or between-group changes in the mMRC scale.
Although PR improves the BODE index in both eosinophilic and noneosinophilic COPD, a higher eosinophil count (≥300 cells/ml) is associated with a higher (worse) BODE index. Blood eosinophils may predict PR outcomes.